bevacizumab | PharmaShots

Samsung Bioepis’ Aybintio (biosimilar, bevacizumab) Receives CHMP’s Positive Opinion to Treat Multiple Cancer Indications

June 29, 2020July 24, 2020Tuba Khan

Shots: The CHMP has recommended the approval of Aybintio in the EU to treat mCRC, mBC, NSCLC, mRCC, epithelial ovarian, fallopian tube and [Read More...]

Innovent and Eli Lilly Report Results of TYVYT (sintilimab) in P-II ORIENT-2 Study as 2L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Innovent Receives the NMPA’s Approval for Byvasda (biosimilar, bevacizumab) to Treat Non-Small Cell Lung Cancer and Metastatic Colorectal Cancer in China

June 19, 2020July 3, 2020Shiwani Sharma

Shots: The NMPA has approved Byvasda for the treatment of patients with NSCLC and metastatic colorectal cancer. The approval follows TYVYT (sintilimab injection) [Read More...]

Henlius Reports the NMPA’s Acceptance of IND for HLX14 (biosimilar, denosumab)

Henlius Reports Positive Results of HLX04 (biosimilar, bevacizumab) in P-III Trial for Metastatic Colorectal Cancer

June 16, 2020July 3, 2020Shiwani Sharma

Shots: HLX04 is a biosimilar that binds to vascular endothelial growth factor (VEGF) for inhibiting angiogenesis where VEGF acts for promoting growth of [Read More...]

Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study in Chinese Patients with Hepatocellular Carcinoma

February 7, 2020February 7, 2020Tuba Khan

Shots: The P-III IMbrave150 study involves assessing Tecentriq (IV, 1200mg) + Avastin (IV, 15mg/kg) vs Sorafenib (400mg, bid) in 501 (194 from China) [Read More...]

Bio-Thera Reports NMPA’s Acceptance of IND for BAT2206 Proposed Biosimilar of Stelara (Ustekinumab)

Bio-Thera Reports Results of BAT1706 (biosimilar, bevacizumab) in P-III Trial for Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

February 4, 2020February 12, 2020Shiwani Sharma

Shots: The P-III study involves assessing of BAT1706 vs EU Avastin (bevacizumab) + chemotherapy in patients with non-squamous NSCLC, evaluating its safety, efficacy, [Read More...]

Roche Reports Submission of sBLA to the US FDA for Tecentriq (atezolizumab) + Avastin (bevacizumab) to Treat Unresectable Hepatocellular Carcinoma

January 27, 2020January 27, 2020Tuba Khan

Shots: The sBLA is based on P-III IMbrave150 study involve assessing of Tecentriq (1200mg, IV) + Avastin (IV, 15 mg/kg) vs Sorafenib (PO, [Read More...]

Coherus Signs a License Agreement with Innovent Biologics to Commercialize Biosimilar of Avastin (bevacizumab) in the US and Canada

January 14, 2020February 12, 2020Tuba Khan

Shots: Innovent to receive $45M as upfront, development & regulatory milestone and royalties on sales of the therapy in the licensed territories while [Read More...]

AstraZeneca’s Lynparza (olaparib) + Bevacizumab Receive the US FDA’s Priority Review for 1L Treatment of Advanced Ovarian Cancers

January 13, 2020January 13, 2020Tuba Khan

Shots: The US FDA has accepted the sNDA and granted the PR for Lynparza in combination with bevacizumab as a maintenance therapy for [Read More...]

Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carcinoma at ESMO Congress 2019

November 25, 2019February 13, 2020Tuba Khan

Shots: The P-III IMbrave150 study involve assessing of Tecentriq (1200mg, IV) + Avastin (IV, 15 mg/kg) vs Sorafenib (PO, 400mg, bid) in 501 [Read More...]

Samsung Bioepis Reports FDA’s Acceptance of BLA for SB8 (biosimilar, bevacizumab)

November 19, 2019November 20, 2019Tuba Khan

Shots: The US FDA has accepted the BLA for review under the 351(k)pathway for its biosimilar candidate, SB8 referencing Avastin (bevacizumab) which was [Read More...]